Drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses significant challenges. The treatment regimens for these forms of TB are longer and involve second-line drugs that have increased toxicity. Newer drugs like bedaquiline and delamanid have been introduced, but they also come with their own toxicity profiles.
